Carole Ho

Carole Ho serves as Chief Medical Officer and Head of Development at Denali Therapeutics since June 2015. Additionally, Carole holds director positions on the Board of Directors for NGM Biopharmaceuticals and Beam Therapeutics Inc., starting in June 2020 and November 2018, respectively. Previously, Carole was Vice President of Clinical Development at Genentech from October 2007 to June 2015 and Associate Medical Director at JNJ / ALZA Corporation for a brief period in 2006-2007. Carole began an academic career as an Instructor at Stanford University School of Medicine from 2002 to 2006. Educational qualifications include a Post-doctoral fellowship in Neurobiology from Stanford University, a Neurology Residency from Harvard University, an MD with Honors in Research from Joan & Sanford I. Weill Medical College of Cornell University, and an SB in Biochemical Sciences, Magna Cum Laude, from Harvard University. Carole's foundational education took place at the Illinois Mathematics and Science Academy.